Review of bupropion for smoking cessation

References

• Australian Institute of Health and Welfare. The quantifi- cation of drug-caused morbidity and mortality in Australia, 1998. Canberra: Australian Institute of Health and Welfare, 2001.
   Google Scholar
• Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation intervention for health care system. Thorax 1998;53(Suppl. 5): S1-19
   Google Scholar
• Cinciripini PM, McClure JB. Smoking cessation: recent developments in behavioural and pharmacological inter- ventions. Oncology 1998;12:249–59.
   PubMed Web of Science ®Google Scholar
• World Health Report. Geneva: WHO, 1999.
   Google Scholar
• Peto R, Lopez A. The future of worldwide smoking patterns. In: Koop CE, Pearson C, Schwarz R, eds. Critical issues in global health. New York: Jossey-Bass, 2000:154–61.
   Google Scholar
• Fiore MC, Novotny TE, Pierce JP et al. Methods used to quit smoking in the United States: do smoking cessation programs help? JAMA 1990;263:2760–5.
   PubMed Web of Science ®Google Scholar
• Fiore MC, Bailey WC, Cohen ST, Dorfman SF, Gold- stein MG, Gritz ER. Treating tobacco use and depen- dence: clinical practice guidelines. Rockville, MD: US Department of Health and Human Services, Public Health Service, 2000.
   Google Scholar
• Centers for Disease Control and Prevention. Smoking cessation during previous year among adults—United States, 1990 and 1991. MMWR 1993;42:504–7.
   Google Scholar
• Cohen S, Lichtenstein E, Prochaska JO et al. Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psychol 1989;44:1355–65.
   Google Scholar
• Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and depen- dence: a US Public Health Service Report. JAMA 2000;283:3244–54.
   Google Scholar
• Hunt WA, Bespalec DA. An evaluation of current methods of modifying smoking behaviour. J Clin Psychol 1974;30:431–8.
   PubMed Web of Science ®Google Scholar
• Peto R, Darby S, Deo H, Silocks P, Whitely E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br Med J 2000;321:323–9.
   PubMed Web of Science ®Google Scholar
• Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the lung health Study. Am J Resp Crit Care Med 2000;161:381–90.
   PubMed Web of Science ®Google Scholar
• Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 1998;53:S1–38.
   Google Scholar
• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S–9.
   PubMed Web of Science ®Google Scholar
• Buck DJ, Richmond RL, Mendelsohn CP. Cost-effective- ness analysis of a family physician delivered smoking cessation program. Prev Med 2000;31:641–8.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Nicotine repla- cement therapy (NRT) and bupropion for smoking cessa- tion. Technology Appraisal Guidance no. 38. London: National Institute for Clinical Excellence, March 2002.
   Google Scholar
• Lancaster T, Stead L, Silagy C, Sowden A, for the Cochrane Tobacco Addiction Review Group. Effective- ness of interventions to help people stop smoking: findings from the Cochrane Library. Br Med J 2000;321:355–8.
   Google Scholar
• Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation: who will quit with and without the nicotine patch? JAMA 1994;271:589–94.
   PubMed Web of Science ®Google Scholar
• Westman EC, Behm FM, Simel DL, Rose JE. Smoking behaviour on the first day of a quit attempt predicts long- term abstinence. Arch Intern Med1997;157:335–40.
   Google Scholar
• Hughes JR. Non-nicotine pharmacotherapies for smoking cessation. J Drug Devel 1994;6:197–203.
   Google Scholar
• Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999;281:72–6.
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Treating tobacco addiction-nicotine or no nicotine? N Engl J Med 1997;337:1230–1.
   PubMed Web of Science ®Google Scholar
• Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002;288:1260–4.
   PubMed Web of Science ®Google Scholar
• Ascher JA, Cole JO, Colin JN et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395–401.
   PubMed Web of Science ®Google Scholar
• Dale LC, Hurt RD, Hays JT. Drug therapy to aid in smoking cessation. Postgrad Med 1998;104:75–84.
   PubMed Web of Science ®Google Scholar
• Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Tobacco Use Cessation 1999;26:653–69.
   Google Scholar
• Leshner AL. Understanding drug addiction: implications for treatment. Hosp Pract 1996;Oct 15:47–59.
   Google Scholar
• Ahluwalia JS, Winter PD, Tucker VL. Summary of safety profile of bupropion HCl (Zyban) [poster]. Society for Research on Nicotine and Tobacco. London, 25-26 November, 1999.
   Google Scholar
• Glassman AH, Helzer JE, Covey LS et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546–9.
   PubMed Web of Science ®Google Scholar
• Hall S, Munoz R, Reus V. Smoking cessation, depression and dysphoria. NIDA Res Monr 1991;105:312–13.
   Google Scholar
• Glass R. Blue mood, blackened lungs: depression and smoking. JAMA 1990;264:1583–4.
   PubMed Web of Science ®Google Scholar
• Covey L, Glassman A, Stetner F. Depression and depressive symptoms in smoking cessation. Comp Psy- chiatry 1990;31:350–4.
   PubMed Web of Science ®Google Scholar
• Hall S, Munoz R, Reus V. Cognitive-behavioural inter- vention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 1994;62:141–6.
   PubMed Web of Science ®Google Scholar
• Shiffman S. Relapse following smoking cessation: a situational analysis. J Consult Clin Psychol 1982;50:71–86.
   PubMed Web of Science ®Google Scholar
• Velicer WF, Prochaska JO, Rossi JS, Snow MG. Assessing outcome in smoking cessation studies. Psychol Bull 1992;111:23–41.
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685–91.
   PubMed Web of Science ®Google Scholar
• Hughes J, Keely J, Niaura R, Ossip-Klein D, Richmond R, Swan G (SRNT Subcommittee on Abstinence Measures). Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tobacco Res 2003, in press.
   Google Scholar
• Velicer WF, Prochaska JO. A comparison of four smoking cessation outcome measures. Society for Research on Nicotine and Tobacco. Seattle WA, March 2001.
   Google Scholar
• Roth M, Westman MD. Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation pro- gram. Pharmacotherapy 2001;21:636–41.
   PubMedGoogle Scholar
• Tashkin D, Kanne R, Bailey W et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double blind placebo-controlled randomised trial. Lancet 2001;357:1571–5.
   Google Scholar
• Hurt R, Sachs D, Glover E et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195–202.
   Google Scholar
• Jamerson BD, Niedes M, Jorenby DE et al. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy and placebo. Clin Ther 2001;23:744–52.
   PubMed Web of Science ®Google Scholar
• Bolliger C, van Spiegel P, Gilljam H, Lebargy F, Town- send J, Hider A, on behalf of the ZybanTM study team. Zyban in a general smoking population (ZYB40017) [poster]. European Respiratory Meeting. Berlin, Septem- ber 2001.
   Google Scholar
• Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2 2003.Oxford: Update Software.
   Google Scholar
• Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994;271:1940–7.
   PubMed Web of Science ®Google Scholar
• Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994;353:139–42.
   Google Scholar
• Hughes JR, Grass JA, Pillitteri JL. Treatment resistant smokers: a pilot study of nicotine nasal spray and inhaler. J Addict Disord 2000;19:95–100.
   PubMed Web of Science ®Google Scholar
• Tonnesen P, Norregaard J, Sawe U, Simonsen K. Recycling with nicotine patches in smoking cessation. Addiction 1993;88:533–9.
   PubMed Web of Science ®Google Scholar
• Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. Br Med J 1995;311:363–6.
   PubMed Web of Science ®Google Scholar
• Gonzales D, Nides M, Ferry L et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001; 69:438–444.
   Google Scholar
• Gonzales D, Nides M, Ferry LH et al. Retreatment with bupropion: results from 12-month follow-up. Society for Research on Nicotine and Tobacco, 8th Annual Meeting, Savannah, GA, 2002.
   Google Scholar
• Nielson K, Fiore MC. Cost-benefit analysis of sustained- release bupropion, nicotine patch, or both for smoking cessation. Prev Med 2000; 30:209–16.
   PubMedGoogle Scholar
• Hall S, Humfleet G, Reus V, Munoz R, Hartz D, Maude- Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002;59:930–6.
   PubMed Web of Science ®Google Scholar
• Roose S, Laghrissi, Thode F et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287–91.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Farsang D, Klaene G et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003, in press.
   Google Scholar
• Mathers C, Vos T, Stevenson C. The burden of disease and injury in Australia. Canberra: Australian Institute of Health and Welfare, 1999.
   Google Scholar
• COPD. Australian and New Zealand management guide- lines and the COPD handbook. 2002; http://www.lungne- t.org.au/COPDHandbook.pdf
   Google Scholar
• Pauwels RA. National and international guidelines for COPD: the need for evidence. Chest 2000;117:20–2S.
   Web of Science ®Google Scholar
• Tonstad S. Use of sustained-release bupropion in specific patient populations for smoking cessation. Drugs 2002;62(Suppl 2):37-43.
   Google Scholar
• Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993–7.
   PubMed Web of Science ®Google Scholar
• Glassman AH, Stetner F, Walsh BT et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind randomized trial. JAMA 1988;259:2863–6.
   PubMed Web of Science ®Google Scholar
• Borrelli B, Niaura R, Keuthen NJ et al. Development of major depressive disorder during smoking cessation treatment. J Clin Psychiatry 1996;57:534–8.
   PubMed Web of Science ®Google Scholar
• Tsoh JY, Humfleet GL, Munoz RF, Reus VI, Hartz DT, Hall SM. Development of major depressive disorder during smoking cessation. Am J Psychiatry 2000;157:368–74.
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Kambhampati RK, Perkins K et al. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. J Clin Psychiatry 2001;62:503–8.
   Google Scholar
• Masironi R. Doctors as non-smoking exemplars. In: Richmond R, ed. Educating medical students about tobacco: planning and implementation. Sydney: IUATLD, 1996:299.
   Google Scholar
• Puska PMJ, Brath H, Astbury C, Hider AE, Jones S. Bupropion SR (Zyban1) is an effective and well-tolerated aid to smoking cessation in a population of healthcare professionals [poster]. Society for Research into Nicotine and Tobacco 4th Conference. Paris, September 2001.
   Google Scholar
• Giuntini C, Barrueco M, Astbury C, Hider AE, Hogue SL. Involvement of healthcare professionals in a smoking- cessation program positively benefits attitudes towards smoking [poster]. Society for Research into Nicotine and Tobacco 4th Conference; Paris, September 2001.
   Google Scholar
• Hatsukami D, Rennard S, Malcolm R, Jamerson BD, Dozier G, Patel MK. A multicentre study examining the effects of Zyban1 (bupropion SR) vs placebo as an aid to smoking reduction leading to cessation among smokers unwilling or unable to quit smoking [poster]Society for Research into Nicotine and Tobacco 4th Conference, Paris, September 2001.
   Google Scholar
• DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process of smoking cessation: an analysis of precontemplation, contemplation and preparation stages of change. J Consult Clin Psychol 1991;59:295–304.
   PubMed Web of Science ®Google Scholar
• Hays JT, Hurt RD, Rigotti NA et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. Ann Intern Med 2001;135:423–33.
   PubMed Web of Science ®Google Scholar
• Gonzales D, Bjornson WM, Durcan MJ et al. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prev Med 2002;22:234–9.
   PubMed Web of Science ®Google Scholar
• Hertzberg MA, Moore SD, Feldman ME. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol 2001;21:94–8.
   PubMed Web of Science ®Google Scholar
• Ferry LH, Burchette RJ. Efficacy of bupropion for smoking cessation in non-depressed smokers. J Addict Disord 1994;13:249.
   Web of Science ®Google Scholar
• Richmond RL, Webster IW. Blood cotinine, carboxyhae- moglobin and thiocyanate measurements related to cigar- ette consumption. Br Med J 1986;6557:293.
   Google Scholar
• Hayford KE, Patten CA, Rummans TA et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999;174:173–8.
   PubMed Web of Science ®Google Scholar
• Williamson DF, Madans J, Anda R, Kleinman JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991;324:739–45.
   PubMed Web of Science ®Google Scholar
• Grunberg NE, Popp KA, Bowen DJ, Nespor SM, Winders SE, Eury SE. Effects of chronic nicotine administration on insulin, glucose, epinephrine, and norepinephrine. Life Sci 1988;42:161–70.
   PubMedGoogle Scholar
• Carney RM, Goldberg AP. Weight gain after cessation of cigarette smoking: a possible role for adipose-tissue lipoprotein lipase. N Engl J Med 1984;310:614–16.
   PubMedGoogle Scholar
• Hofstetter A, Schutz Y, Jequier E, Wahren J. Increased 24- hour energy expenditure in cigarette smokers. N Engl J Med 1986;314:79–82.
   PubMed Web of Science ®Google Scholar
• Grunberg NE, Bowen DJ, Maycock VA, Nespor SM. The importance of sweet aste and caloric content in the effects of nicotine on specific food consumption. Psychopharma- cology 1985;87:198–203.
   PubMed Web of Science ®Google Scholar
• Perkins KA, Epstein LH, Marks BL, Stiller RL, Jacob RG. The effect of nicotine on energy expenditure during light physical activity. N Engl J Med 1989;320:898–903.
   PubMedGoogle Scholar
• Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. DHHS publication no. (CDC) 90-8416. Wa- shington, DC: Government Printing Office, 1990.
   Google Scholar
• Rigotti NA, Thorndike AN, Durcan MJ et al. Post- cessation weight gain in smokers taking bupropion: the effect of gender. Society for Research on Nicotine & Tobacco 6th Conference. Arlington, Virginia, 2000.
   Google Scholar
• Gadde KM, Parker CB, Maner LG et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obesity Res 2001;9:544–51.
   PubMedGoogle Scholar
• Benson E. Bupropion-induced hypersensitivity reactions. Med J Aust 2001;174:650–51.
   PubMed Web of Science ®Google Scholar
• Dunner DL, Zisook S, Billow A, Batey S, Johnston JA, Ascher J. A prospective safety surveillance study for bupropion sustained-release in the treatment of depres- sion. J Clin Psychiatry 1998;59:366–73.
   PubMed Web of Science ®Google Scholar
• Johnston JA, Lineberry CG, Ascher JA et al. A 102-centre prospective study of seizure in association with bupropion. J Clin Psychiatry 1991;52:450–6.
   PubMed Web of Science ®Google Scholar
• Holm KJ, Spencer CM. Bupropion. A review of its use in the management of smoking cessation. Drugs 2000;59:1007–24.
   Google Scholar
• GlaxoSmithKline. Approved Product Information for Zyban1 2001.
   Google Scholar
• Zwar N, Richmond R. Therapeutic review of bupropion sustained-release (ZybanTM). Aust Family Physician 2002; 31:443–7.
   PubMedGoogle Scholar
• Chapman SC, Jamrozik K. Is bupropion (Zyban) causing deaths? Med J Aust 2002; 176: 134.
   PubMedGoogle Scholar
• ADRAC Therapeutic Good Administration. Update on Bupropion (Zyban SR). 31 August 2001. www.health.go- v.au/tga/docs/html/zyban.htm
   Google Scholar
• Medicines Control Agency. Zyban (bupropion hydro- chloride)—safety update. Committee on Safety of Medi- cines, July 2002. www.mca.gov.uk/aboutagency/regframe work/csm/csmhome.htm
   Google Scholar
• Glaxo Wellcome. Bupropion hydrochloride sustained- release tablets prescribing information. Research Triangle Park, North Carolina, 1999.
   Google Scholar
• Glaxo Wellcome, Zyban1 Product Monograph, Ontario, Canada, 1998.
   Google Scholar
• Glaxo Wellcome. Zyban 150 mg prolonged-release tablets (bupropion hydrochloride). Summary of Product Char- acteristics, June 2000.
   Google Scholar
• Harmon T, Kurta D, Krenzelok EP. Delayed seizures from sustained-release bupropion overdose. J Toxicol Clin Toxicol 1998;36:522.
   Google Scholar
• Shrier M, Diaz JE, Tsarouhas N. Cardiotoxicity associated with bupropion overdose. Ann Emerg Med 2000;35:100
   Google Scholar
• Paris PA, Saucier JR. ECG conduction delays associated with massive bupropion overdose. J Toxicol Clin Toxicol 1998;36:595–8.
   PubMed Web of Science ®Google Scholar
• Weiner A, Nowicki T, Bayer M et al. Zyban (bupropion) overdose [abstract]. J Toxicol Clin Toxicol 1998;36:521–2.
   Google Scholar
• Spiller HA, Ramoska EA, Krenzelok EP et al. Bupropion in overdose: a 3-year multi-centre retrospective analysis. Am J Emerg Med 1994;12:43–5.
   PubMed Web of Science ®Google Scholar